计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
Moligand™ 级 提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,避光,充氩。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC 50 s of 1 nM for p70S6K , Akt1 and Akt3 . M2698 can cross the blood-brain barrier and has anti-cancer activity
In Vitro
M2698 (0.3 nM to 50 M; 72 hours) inhibits proliferation in a dose-dependent manner in breast tumors cell lines with IC 50 s of 0.02-8.5 µM. M2698 (0.3, 1 µM; 24 hours) inhibits p70S6K activity and induces feedback loop phosphorylation on Akt and suppresses Akt activity in breast cancer cell lines. M2698 inhibits indirectly pGSK3β (IC 50 =17 nM) and pS6 (IC 50 =15 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Breast tumors cell lines Concentration: 0.3 nM to 50 M Incubation Time: 72 hours Result: Inhibited proliferation in a dose-dependent manner. Western Blot AnalysisCell Line: HCC1419 and MDA-MB-453 cells Concentration: 0.3, 1 µM Incubation Time: 24 hours Result: Inhibited p70S6K activity and induced feedback loop phosphorylation on Akt and suppressed Akt activity in breast cancer cell lines.
In Vivo
M2698 (10-30 mg/kg/day; PO; 28 days) results in dose-dependent inhibition of tumor growth and results in tumor regression with the highest dose of 30 mg/kg . M2698 (20 mg/kg/day; PO; 4 days) has a tumor:plasma exposure ratio of 12:1 over 24 hours and leads to increased levels of pAkt in tumor tissue . The mean total concentration of M2698 after 16-hour infusion in rats is 1750 ng/g and 175 ng/mL in brain and plasma, respectively . M2698 (po; 1, 5, 10, or 20 mg/kg/day; for 7 days) inhibits the phosphorylation of S6 in a dose-proportional manner over time after a single administration or daily treatments over 7 days . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female nude mice bearing MDA-MB-468 tumors Dosage: 10, 20 and 30 mg/kg Administration: PO; daily; for 28 days Result: Resulted in dose-dependent inhibition of tumor growth and resulted in tumor regression with the highest dose of 30 mg/kg. Animal Model: Female SCID Beige mice with MDA-MB-453 xenografted Dosage: 20 mg/kg (Pharmacokinetic Analysis) Administration: Daily; for 4 days Result: Had a tumor:plasma exposure ratio of 12:1 over 24 hours.
Form:Solid
IC50& Target:p70S6K 1 nM (IC 50 ) Akt1 1 nM (IC 50 ) Akt3 1 nM (IC 50 )
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 二氮杂萘 |
| 亚类(Subclass) | 苯二嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 喹唑啉 |
| 直接上位类(Direct Parent) | 喹唑啉胺 |
| 其他上位类(Alternative Parents) | 三氟甲基苯 氨基嘧啶及其衍生物 芳烷基胺 氯苯类 芳基氯化物 咪唑内酰胺类 杂芳族化合物 三烷基胺 伯羧酸酰胺 氨基酸及其衍生物 氮杂环丁烷 氮杂环化合物 碳氢化合物衍生物 有机氧化物 有机氯化物 有机氟化物 有机氧化合物 烷基氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳烷基胺 - 芳香族杂多环化合物 - 芳基氯化物 - 芳基卤化物 - 氮杂环 - 氮杂环丁烷 - 苯基化合物 - 羧酰胺基 - 羧酸衍生物 - 氯苯 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 单环苯基基团 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氯化物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 醛基胺 - 嘧啶 - 萘啶吡啶 - 三元脂肪胺 - 三芳基胺 - 三氟甲基苯 |
| 描述(Description) | 该化合物属于喹唑啉胺类有机化合物。这类杂环芳香化合物含有喹唑啉骨架,其上取代有一个或多个胺基。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 3.9 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|